Pfizer Inc. (NYSE:PFE) was the recipient of a large decline in short interest in October. As of October 31st, there was short interest totalling 46,551,071 shares, a decline of 7.5% from the October 15th total of 50,351,438 shares. Approximately 0.8% of the company’s shares are short sold. Based on an average daily volume of 26,087,863 shares, the short-interest ratio is presently 1.8 days.

NYSE:PFE opened at $43.52 on Wednesday. Pfizer has a one year low of $33.20 and a one year high of $45.81. The company has a debt-to-equity ratio of 0.47, a quick ratio of 1.15 and a current ratio of 1.43. The stock has a market cap of $263.59 billion, a P/E ratio of 16.42, a price-to-earnings-growth ratio of 2.23 and a beta of 0.88.

Pfizer (NYSE:PFE) last posted its quarterly earnings data on Tuesday, October 30th. The biopharmaceutical company reported $0.78 EPS for the quarter, topping the consensus estimate of $0.75 by $0.03. Pfizer had a net margin of 44.63% and a return on equity of 25.26%. The business had revenue of $13.30 billion for the quarter, compared to analyst estimates of $13.53 billion. During the same quarter in the previous year, the firm posted $0.67 earnings per share. Pfizer’s quarterly revenue was up 1.0% on a year-over-year basis. Research analysts anticipate that Pfizer will post 3 EPS for the current fiscal year.

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, December 3rd. Investors of record on Friday, November 9th will be paid a dividend of $0.34 per share. This represents a $1.36 annualized dividend and a yield of 3.13%. The ex-dividend date is Thursday, November 8th. Pfizer’s payout ratio is currently 51.32%.

PFE has been the topic of a number of research reports. Cantor Fitzgerald set a $45.00 target price on shares of Pfizer and gave the company a “buy” rating in a research note on Thursday, October 4th. Morgan Stanley set a $45.00 target price on shares of Pfizer and gave the company a “buy” rating in a research note on Wednesday, August 29th. Credit Suisse Group lifted their target price on shares of Pfizer from $39.00 to $40.00 and gave the company a “neutral” rating in a research note on Wednesday, August 1st. Bank of America lifted their target price on shares of Pfizer from $42.00 to $43.00 and gave the company a “buy” rating in a research note on Wednesday, August 1st. Finally, Goldman Sachs Group reaffirmed a “neutral” rating and set a $45.00 target price on shares of Pfizer in a research note on Tuesday, October 30th. Two investment analysts have rated the stock with a sell rating, fifteen have given a hold rating and eight have issued a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and a consensus target price of $42.67.

In related news, major shareholder Pfizer Inc bought 55,556 shares of the business’s stock in a transaction dated Monday, October 15th. The shares were purchased at an average price of $18.00 per share, with a total value of $1,000,008.00. Following the purchase, the insider now owns 21,976,484 shares of the company’s stock, valued at approximately $395,576,712. The acquisition was disclosed in a document filed with the SEC, which is available through the SEC website. Insiders own 0.06% of the company’s stock.

Large investors have recently bought and sold shares of the stock. Chase Investment Counsel Corp lifted its stake in shares of Pfizer by 16.2% in the third quarter. Chase Investment Counsel Corp now owns 8,384 shares of the biopharmaceutical company’s stock worth $369,000 after buying an additional 1,169 shares in the last quarter. Schaper Benz & Wise Investment Counsel Inc. WI raised its holdings in shares of Pfizer by 0.5% during the third quarter. Schaper Benz & Wise Investment Counsel Inc. WI now owns 228,630 shares of the biopharmaceutical company’s stock valued at $10,076,000 after purchasing an additional 1,170 shares during the last quarter. Clean Yield Group raised its holdings in shares of Pfizer by 1.9% during the third quarter. Clean Yield Group now owns 64,375 shares of the biopharmaceutical company’s stock valued at $2,837,000 after purchasing an additional 1,170 shares during the last quarter. Eagle Capital Management LLC raised its holdings in shares of Pfizer by 1.4% during the third quarter. Eagle Capital Management LLC now owns 84,453 shares of the biopharmaceutical company’s stock valued at $3,722,000 after purchasing an additional 1,173 shares during the last quarter. Finally, Adams Asset Advisors LLC raised its holdings in shares of Pfizer by 0.8% during the third quarter. Adams Asset Advisors LLC now owns 157,717 shares of the biopharmaceutical company’s stock valued at $6,951,000 after purchasing an additional 1,182 shares during the last quarter. 69.08% of the stock is currently owned by institutional investors and hedge funds.

TRADEMARK VIOLATION WARNING: This article was originally published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this article on another publication, it was illegally copied and reposted in violation of United States and international copyright & trademark laws. The original version of this article can be read at https://www.thecerbatgem.com/2018/11/14/pfizer-inc-pfe-sees-significant-drop-in-short-interest.html.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It operates in two segments, Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). The IH segment focuses on the development and commercialization of medicines and vaccines, and consumer healthcare products in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases, as well as consumer healthcare, such as over-the-counter brands comprising dietary supplements, pain management, gastrointestinal, and respiratory and personal care.

Featured Story: Benefits of owning preferred stock

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.